Nanocovax

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNanocovax
Drug Alias NameRecombinant SARS-CoV-2 Spike protein, Aluminum adjuvanted
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryVietnam
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNanogen Pharmaceutical Biotechnology Joint Stock Company
China Registration ClassN/A

Develop Information

Active CompaniesNanogen Pharmaceutical Biotechnology Joint Stock Company
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A